Substance / Medication

Ozanimod

Overview

Active Ingredient
ozanimod
RxNorm CUI
2288236

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
3
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.
Cohan Stanley, Tencer Tom, Arndorfer Stella et al. · Mult Scler Relat Disord · 2021
PMID: 33979770Meta-Analysis
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.
Yarur Andres, Irving Peter, Siegmund Britta et al. · Inflamm Bowel Dis · 2026
PMID: 41003640RCTFull text (PMC)
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.
Sands Bruce E, Rubin David T, Loftus Edward V et al. · Am J Gastroenterol · 2025
PMID: 39773524RCTFull text (PMC)
Ozanimod Therapy in Patients With COVID-19 Requiring Oxygen Support: A Randomized Open-Label Pilot Trial.
Lellouche François, Blais-Lecours Pascale, Maltais François et al. · Chest · 2024
PMID: 37898184RCT
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Sands Bruce E, D'Haens Geert, Panaccione Remo et al. · Clin Gastroenterol Hepatol · 2024
PMID: 38723981RCT
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
Feagan Brian G, Schreiber Stefan, Afzali Anita et al. · Contemp Clin Trials · 2022
PMID: 36208720RCTFull text (PMC)
Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis.
Kochhar Gursimran S, Khataniar Himsikhar, Hashash Jana G et al. · Inflamm Bowel Dis · 2025
PMID: 39478367Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ozanimod (substance)
SNOMED CT
870525003
UMLS CUI
C4278675
RxNorm CUI
2288236

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.